Academic Journal
A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1)
| العنوان: | A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1) |
|---|---|
| المؤلفون: | Kathleen Ruchalski, Jordan M. Anaokar, Matthias R. Benz, Rohit Dewan, Michael L. Douek, Jonathan G. Goldin |
| المصدر: | Cancer Imaging, Vol 24, Iss 1, Pp 1-7 (2024) |
| بيانات النشر: | BMC, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | RECIST, Progression free survival., Disease progression, Biomarkers, Tumor, Clinical trial, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract The Response Evaluation in Solid Tumors (RECIST) 1.1 provides key guidance for performing imaging response assessment and defines image-based outcome metrics in oncology clinical trials, including progression free survival. In this framework, tumors identified on imaging are designated as either target lesions, non-target disease or new lesions and a structured categorical response is assigned at each imaging time point. While RECIST provides definitions for these categories, it specifically and objectively defines only the target disease. Predefined thresholds of size change provide unbiased metrics for determining objective response and disease progression of the target lesions. However, worsening of non-target disease or emergence of new lesions is given the same importance in determining disease progression despite these being qualitatively assessed and less rigorously defined. The subjective assessment of non-target and new disease contributes to reader variability, which can impact the quality of image interpretation and even the determination of progression free survival. The RECIST Working Group has made significant efforts in developing RECIST 1.1 beyond its initial publication, particularly in its application to targeted agents and immunotherapy. A review of the literature highlights that the Working Group has occasionally employed or adopted objective measures for assessing non-target and new lesions in their evaluation of RECIST-based outcome measures. Perhaps a prospective evaluation of these more objective definitions for non-target and new lesions within the framework of RECIST 1.1 might improve reader interpretation. Ideally, these changes could also better align with clinically meaningful outcome measures of patient survival or quality of life. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1470-7330 |
| Relation: | https://doaj.org/toc/1470-7330 |
| DOI: | 10.1186/s40644-024-00802-8 |
| URL الوصول: | https://doaj.org/article/f0746d41cb1d4075b886e334a5f2969b |
| رقم الانضمام: | edsdoj.f0746d41cb1d4075b886e334a5f2969b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14707330 |
|---|---|
| DOI: | 10.1186/s40644-024-00802-8 |